---

Chronic Progressive Dyspnea & Cough in an 80-Year-Old — Diagnosis & Management

---

Step 1: Differential Diagnosis

In the elderly, COPD and HF frequently coexist and can both be present simultaneously.

---

Most Probable Diagnosis: COPD

Pathophysiology

• COPD is characterised by airflow limitation that is not fully reversible, caused by an abnormal inflammatory response to noxious stimuli (predominantly cigarette smoke).
• Chronic bronchitis: persistent productive cough ≥3 months/year for ≥2 consecutive years, due to mucous gland hyperplasia and goblet cell metaplasia.
• Emphysema: enlargement of air spaces distal to terminal bronchioles from protease-mediated destruction of elastic support structures (mainly by neutrophil-released elastases).
• In elderly patients, dynamic hyperinflation is the dominant cause of exertional dyspnea. Insufficient expiratory time leads to air trapping, increased end-expiratory lung volume, reduced inspiratory reserve volume, and diaphragmatic flattening — creating progressive neuromechanical uncoupling and breathlessness. — Fishman's Pulmonary Diseases and Disorders
• Hypercapnia typically develops when FEV₁ falls to ~20–25% predicted and carries a poor prognosis (shorter survival, higher rehospitalisation rates). — Fishman's Pulmonary Diseases and Disorders, p.2532

---

Investigations

Essential

GOLD Severity Staging (post-bronchodilator FEV₁)

---

Management

Non-Pharmacological

1. Smoking cessation — single most effective intervention to slow progression; refer to cessation services regardless of age.
2. Pulmonary rehabilitation — structured exercise + education; improves exercise tolerance and quality of life. A 2026 systematic review (PMID: 39831582) confirms nurse-led home-based rehabilitation is effective in older COPD patients.
3. Vaccinations: Influenza (annually), Pneumococcal (PCV15/PCV20 or PPSV23), COVID-19, and RSV (in older adults).
4. Nutritional support — COPD causes muscle wasting; adequate caloric intake is important.
5. Long-term oxygen therapy (LTOT): If resting PaO₂ ≤ 55 mmHg (or ≤ 59 mmHg with cor pulmonale/polycythaemia) on room air — prescribed for ≥15 hours/day.

Pharmacological (step-up by GOLD group)

Short-acting bronchodilators (rescue/PRN)

• SABA: Salbutamol (albuterol) MDI — for acute symptom relief
• SAMA: Ipratropium bromide MDI — or in combination with SABA
• "For relief of acute symptoms, inhalation of a short-acting β-agonist (e.g., albuterol), of an anticholinergic drug (e.g., ipratropium bromide), or the two in combination is usually effective." — Katzung's Pharmacology, p.565

Maintenance bronchodilators (regular use for persistent dyspnea)

Regular use of a LABA or long-acting anticholinergic, or the two together, is the standard of care for persistent exertional dyspnea. — Katzung's Pharmacology

Inhaled corticosteroids (ICS)

• NOT first-line in COPD (unlike asthma); risk of bacterial pneumonia
• Indicated in: GOLD grade 3–4 + frequent exacerbations or blood eosinophils ≥ 300 cells/μL (or asthma-COPD overlap)
• Used as triple therapy: LABA + LAMA + ICS (e.g., fluticasone/umeclidinium/vilanterol)
• Blood eosinophils guide ICS benefit: high eosinophils → more likely to benefit — Katzung's Pharmacology, p.565

Additional agents

• Roflumilast (PDE-4 inhibitor): reduces exacerbation frequency in severe COPD with chronic bronchitis phenotype; approved for add-on therapy
• Azithromycin (long-term, low dose): reduces exacerbation frequency in selected patients; check QTc before use in elderly
• Mucolytics (carbocisteine, N-acetylcysteine): may reduce exacerbations; consider in chronic bronchitis

Management of Acute Exacerbations (AECOPD)

1. Controlled oxygen — target SpO₂ 88–92% (avoid over-oxygenation → hypercapnia)
2. Nebulised SABA + SAMA (salbutamol + ipratropium)
3. Systemic corticosteroids: prednisolone 40 mg oral × 5 days
4. Antibiotics: if purulent sputum or increased dyspnea — β-lactam (amoxicillin-clavulanate), doxycycline, or azithromycin — Katzung's Pharmacology
5. NIV (Non-invasive ventilation): CPAP/BiPAP if hypercapnic respiratory failure (pH <7.35, PaCO₂ >45 mmHg) — Fishman's Pulmonary Diseases, p.2532
6. Invasive ventilation: last resort if NIV fails

---

Special Considerations in the Elderly (80 years)

---

Summary Algorithm

Chronic progressive dyspnea + cough in 80-year-old
               ↓
       Spirometry (FEV₁/FVC < 0.70 post-BD) → COPD confirmed
               ↓
    Assess severity (GOLD 1–4) + symptom burden (mMRC/CAT score)
               ↓
    Smoking cessation + Vaccinations + Pulmonary rehab
               ↓
    SABA/SAMA PRN → Add LAMA → Add LABA → Add ICS (if indicated)
               ↓
   If frequent exacerbations: + Roflumilast or long-term Azithromycin
               ↓
    If SpO₂ ≤88%: Long-term oxygen therapy (≥15 h/day)
               ↓
    Exacerbation: O₂ (88–92%) + Neb SABA/SAMA + Steroids + Abx ± NIV

---